Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Zydus Lifesciences's work in process for the quarter that ended in Mar. 2026 was ₹6,864 Mil.
Zydus Lifesciences Inventories, Work In Process Historical Data
* Premium members only.
The historical data trend for Zydus Lifesciences's Inventories, Work In Process can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zydus Lifesciences Inventories, Work In Process Chart
Zydus Lifesciences Inventories, Work In Process Calculation
That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.
What does a Inventories, Work In Process of ₹6,864 Mil mean?
Zydus Lifesciences (BOM:532321) has a Inventories, Work In Process of ₹6,864 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Zydus Lifesciences and its competitors.
Is Zydus Lifesciences' Inventories, Work In Process too high?
Zydus Lifesciences' current Inventories, Work In Process is ₹6,864 Mil. Overall, Zydus Lifesciences has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' Inventories, Work In Process compare to ZTS and UTHR?
Zydus Lifesciences' Inventories, Work In Process of ₹6,864 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Drug Manufacturers company?
A good Inventories, Work In Process depends on the Drug Manufacturers industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Zydus Lifesciences and its competitors. Zydus Lifesciences's current Inventories, Work In Process is ₹6,864 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (BOM:532321) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,157.13, compared to a current price of ₹1,129.75 — trading 2.4% below its estimated fair value. The current Inventories, Work In Process is ₹6,864 Mil. Zydus Lifesciences' overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Zydus Lifesciences (BOM:532321), the current Inventories, Work In Process is ₹6,864 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zydus Lifesciences (BOM:532321) Overvalued in 2026?
Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued.
The current stock price of ₹1,129.75 is trading 2.4% below its estimated GF Value™ of ₹1,157.13.
GuruFocus considers Zydus Lifesciences to be Fairly Valued.
Key valuation signals for BOM:532321:
Inventories, Work In Process: ₹6,864 Mil
GF Value™: ₹1,157.13 vs. price of ₹1,129.75 (2.4% below fair value)
No single metric tells the full story. See the BOM:532321 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
95GF Score
Get the complete analysis for BOM:532321
Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532321 has been successfully added to your 
